.svg){kind=icon}
CBD and THC receive most of the attention in medical cannabis education, but Cannabis sativa produces many additional cannabinoids in much smaller concentrations.
One of them is cannabidivarin, or CBDV.
CBDV is chemically related to CBD and is generally considered non-intoxicating. Researchers have studied it most extensively in neurological areas, including seizure disorders and autism spectrum disorder.
The results are scientifically interesting but still preliminary.
Preclinical experiments have identified several potential molecular targets, and CBDV has progressed far enough to be tested in controlled human clinical trials. However, published trials have not yet established CBDV as an approved treatment for epilepsy, autism, or another medical condition.
For Florida medical cannabis patients, CBDV is best viewed as an emerging minor cannabinoid with active clinical research, rather than a compound with established therapeutic effects.
What Is CBDV?
CBDV stands for cannabidivarin.
It is a naturally occurring phytocannabinoid found in Cannabis sativa.
Chemically, CBDV is closely related to cannabidiol, or CBD.
Both share a similar core molecular structure, but their side chains are different.
CBD has a:
five-carbon pentyl side chain
CBDV has a:
three-carbon propyl side chain
That is why CBDV is sometimes described as the propyl analogue of CBD.
This shorter side chain may contribute to differences in the way CBDV interacts with biological targets.
CBDV Belongs to the Varin Cannabinoid Family
Cannabis does not produce only the familiar pentyl cannabinoids such as THC and CBD.
It also produces a related family sometimes called varin cannabinoids.
Examples include:
- CBDV
- THCV
- CBGV
- CBCV
These compounds have shorter three-carbon side chains.
The plant also produces acidic precursors.
For CBDV, the related acidic cannabinoid is CBDVA, or cannabidivarinic acid.
Through decarboxylation:
CBDVA → CBDV
This is similar to:
CBDA → CBD
and
THCA → THC
Heat can accelerate these reactions by removing carbon dioxide from the acidic cannabinoid.
Is CBDV Intoxicating?
CBDV is not known to produce the typical THC-like intoxication associated with strong CB1 receptor activation.
Research suggests CBDV has relatively weak affinity for classical CB1 and CB2 cannabinoid receptors.
That makes its pharmacology different from THC.
However, describing CBDV as non-intoxicating should not be interpreted as meaning that every cannabis product containing CBDV is non-intoxicating.
A product could contain CBDV alongside substantial THC.
The complete cannabinoid profile still matters.
How Does CBDV Work?
Researchers are still determining exactly how CBDV produces its biological effects.
One important research area involves transient receptor potential, or TRP, channels.
Experimental studies have found CBDV activity involving:
- TRPV1
- TRPV2
- TRPA1
- Other TRP channels
TRP channels participate in processes involving:
- Sensory signaling
- Temperature detection
- Pain signaling
- Cellular calcium
- Neuronal excitability
CBDV can activate and then desensitize some of these channels under laboratory conditions.
That has contributed to research interest in neurological disorders.
CBDV and the Endocannabinoid System
CBDV does not behave like THC at CB1 receptors.
However, that does not mean it has no relationship with the broader endocannabinoid system.
Laboratory research has examined CBDV's effects on enzymes and signaling molecules involved in endocannabinoid metabolism.
For example, CBDV has been shown experimentally to affect DAGL-alpha, an enzyme involved in synthesis of the endocannabinoid 2-AG.
The clinical importance of this interaction is not yet clear.
This is a good example of why cannabinoid pharmacology extends beyond CB1 and CB2 receptors.
Why Researchers Studied CBDV for Epilepsy
CBDV attracted substantial interest after laboratory and animal studies reported anticonvulsant-like activity.
Researchers observed changes in experimental models of neuronal hyperexcitability and seizure activity.
This led to human clinical development.
A pharmaceutical CBDV preparation was eventually tested as an add-on therapy in adults with inadequately controlled focal seizures.
That study provides one of the clearest examples of why clinical trials are essential before conclusions are drawn from preclinical cannabinoid research.
What Happened in the Human Seizure Trial?
The Phase 2 trial included 162 participants.
Participants receiving CBDV were titrated up to 800 mg twice daily, while another group received placebo.
Seizure frequency declined approximately 40.5% in the CBDV group.
At first glance, that sounds encouraging.
But seizure frequency also declined about 37.7% in the placebo group.
The difference between CBDV and placebo was not statistically significant.
Researchers also found no significant treatment difference across the secondary seizure outcomes.
Therefore, the trial did not demonstrate that CBDV was superior to placebo for focal seizures in that population.
CBDV Safety Research
CBDV was generally tolerated during the seizure trial, but adverse effects occurred more frequently in the CBDV group than in the placebo group.
Frequently reported effects included:
- Diarrhea
- Nausea
- Somnolence
Several participants receiving CBDV also developed elevated liver enzymes.
These findings reinforce an important medical-cannabis principle:
Non-intoxicating does not mean pharmacologically inactive or risk-free.
Purified cannabinoids at clinical doses can produce measurable biological effects and potential adverse reactions.
CBDV and Autism Spectrum Disorder Research
CBDV has also attracted research interest in autism spectrum disorder.
Scientists have investigated whether CBDV may influence the balance between excitatory and inhibitory signaling within the brain.
Two particularly important neurotransmitter systems are:
- Glutamate
- GABA
Changes in excitation and inhibition have been studied extensively in neurodevelopmental research.
What Human Brain-Imaging Studies Found
In one randomized crossover study, adults with and without autism received a single 600 mg dose of CBDV or placebo.
Researchers used magnetic resonance spectroscopy to measure brain chemistry.
CBDV produced measurable changes in glutamate-related signaling within the basal ganglia.
A related imaging study found changes in functional connectivity within striatal brain circuits.
These are interesting biological findings.
But they should not be interpreted as evidence that CBDV treats autism.
The studies primarily measured brain response, not long-term clinical improvement.
CBDV Autism Clinical Trials Are Still Ongoing
CBDV continues to attract clinical interest.
A Phase 2 randomized, placebo-controlled study has been evaluating CBDV in children and adolescents with autism spectrum disorder.
The study is designed to examine outcomes including irritability and other behavioral measures.
Until controlled results are published and replicated, CBDV should not be presented as an established autism therapy.
That distinction is particularly important when discussing cannabinoids involving children.
CBDV vs CBD
CBDV and CBD share similarities, but evidence from one cannot automatically be transferred to the other.
CBD
CBD has a larger human research base and one FDA-approved prescription formulation for specific seizure disorders.
CBDV
CBDV has considerably less human evidence and currently remains investigational.
They also interact with biological targets somewhat differently.
This means a finding from a CBD study cannot simply be rewritten as a CBDV claim.
Is CBDV Common in Cannabis?
CBDV is usually considered a minor cannabinoid.
It may occur naturally at low concentrations in many cannabis varieties and may be more prominent in certain genetic populations.
Historically, researchers have reported higher CBDV concentrations in some cannabis types associated with higher CBD and lower THC expression.
Modern breeding could potentially increase specific minor cannabinoids, but most dispensary products remain dominated by THC, CBD, or both.
Patients should therefore never assume a strain contains meaningful CBDV based on its name.
How to Read CBDV on a Lab Report
A complete cannabinoid panel might show:
THCA: 22%
Delta-9 THC: 0.8%
CBGA: 0.6%
CBD: 0.1%
CBDV: 0.03%
The CBDV number confirms that the compound was detected.
It does not mean that 0.03% represents the doses tested in pharmaceutical clinical research.
Clinical CBDV studies have administered hundreds or even more than one thousand milligrams per day of purified CBDV.
Trace cannabis concentrations should not be compared directly with those investigational doses.
Current Green Dragon Florida Products for Lab-Profile Comparison
Current public Green Dragon Florida menu data does not consistently provide verified CBDV measurements.
The following current flower products are therefore included as examples for reviewing complete cannabinoid laboratory profiles, not because they are being labeled CBDV-rich.
Green Dragon Butter Cake Blues — Tallahassee Gaines
Green Dragon Butter Cake Blues is currently listed around 18.8% total THC, 0.054% total CBD, and 1.66% total terpenes.
Patients interested in minor cannabinoids should review the Full Lab Data to determine whether compounds such as CBDV, CBG, CBC, or their acidic precursors were detected in the current batch.
Everyday Gelato Sundae — Tallahassee Gaines
Everyday Gelato Sundae is currently listed around 20.2% total THC and 1.03% total terpenes.
Its current menu profile demonstrates why the headline THC percentage provides only part of the chemical picture.
Circles Dry Heat — Ocala
Circles Dry Heat is currently listed around 20.3% total THC, 0.055% total CBD, and 1.40% total terpenes.
Again, patients specifically researching CBDV should use the current full laboratory panel rather than assuming the cultivar name predicts minor-cannabinoid content.
Availability and laboratory profiles can change by Green Dragon Florida location and batch.
The Green Dragon Takeaway
CBDV is an emerging minor cannabinoid with legitimate scientific and clinical interest.
It is structurally related to CBD but has a shorter propyl side chain and somewhat different pharmacology.
Researchers have studied CBDV most extensively in:
- Epilepsy
- Neuronal excitability
- Autism spectrum disorder
- TRP-channel signaling
- Brain excitation and inhibition
Preclinical evidence produced enough interest to move CBDV into human trials.
But results have not yet established it as a clinically proven therapy.
A large focal-seizure study did not show significant benefit over placebo, while autism studies have so far provided primarily mechanistic brain-imaging findings and ongoing clinical investigation.
For medical cannabis patients, CBDV should therefore be viewed as promising research—not established treatment.